Structural Determinants of Buprenorphine Partial Agonism at the μ-Opioid Receptor.  Gomes AAS, Giraldo J.  J Chem Inf Model. 2025 May 26;65(10):5071-5085. doi: 10.1021/acs.jcim.5c00078. Epub 2025 May 6. PMID: 40328437; PMCID: PMC12117568…

Patient-elected low-dose intravenous naloxone for rapid buprenorphine induction: a case report.  Azar P, Machado J, Kim JJ, Wong JSH, Nikoo M, Li VW.  Addict Sci Clin Pract. 2025 May 14;20(1):42. doi: 10.1186/s13722-025-00572-z. PMID: 40…

A Path Forward for Extended-Release Buprenorphine—Optimizing Implementation Strategies.  Assoumou SA, Morgan JR.  JAMA Netw Open. 2025;8(5):e2513010. doi:10.1001/jamanetworkopen.2025.13010 https://jamanetwork.com/journals/jama…

Initiating Injectable Buprenorphine in People Hospitalized With Infections: A Randomized Clinical Trial.  Seval N, Roth P, Frank CA, et al.  JAMA Netw Open. 2025;8(5):e2513000. doi:10.1001/jamanetworkopen.2025.13000…

USA. Seattle nonprofit rolling out potential ‘game changer’ for fentanyl addiction  (…) In the past year, a Seattle-based behavioral health treatment provider has pioneered a method to start people on low doses of injectable, slow-releasing bu…

buprenorphine/naloxone (Rx) Brand and Other Names:Suboxone, Zubsolv, Cassipa: Dosing & Uses, Interactions https://reference.medscape.com/drug/suboxone-zubsolv-buprenorphine-naloxone-343334